Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

The Coming Age of Flavonoids in the Treatment of Diabetic Complications.

Caro-Ordieres T, Marín-Royo G, Opazo-Ríos L, Jiménez-Castilla L, Moreno JA, Gómez-Guerrero C, Egido J.

J Clin Med. 2020 Jan 27;9(2). pii: E346. doi: 10.3390/jcm9020346. Review.

2.

Editorial: Role of Nrf2 in Disease: Novel Molecular Mechanisms and Therapeutic Approaches.

Egea J, González-Rodríguez Á, Gómez-Guerrero C, Moreno JA.

Front Pharmacol. 2019 Oct 4;10:1149. doi: 10.3389/fphar.2019.01149. eCollection 2019. No abstract available.

3.

Role of complement system in pathological remodeling of the vascular wall.

Martin-Ventura JL, Martinez-Lopez D, Roldan-Montero R, Gomez-Guerrero C, Blanco-Colio LM.

Mol Immunol. 2019 Oct;114:207-215. doi: 10.1016/j.molimm.2019.06.016. Epub 2019 Aug 1. Review.

PMID:
31377677
4.

SOCS1-Derived Peptide Administered by Eye Drops Prevents Retinal Neuroinflammation and Vascular Leakage in Experimental Diabetes.

Hernández C, Bogdanov P, Gómez-Guerrero C, Sampedro J, Solà-Adell C, Espejo C, García-Ramírez M, Prieto I, Egido J, Simó R.

Int J Mol Sci. 2019 Jul 24;20(15). pii: E3615. doi: 10.3390/ijms20153615.

5.

Diabetes-mediated promotion of colon mucosa carcinogenesis is associated with mitochondrial dysfunction.

Del Puerto-Nevado L, Santiago-Hernandez A, Solanes-Casado S, Gonzalez N, Ricote M, Corton M, Prieto I, Mas S, Sanz AB, Aguilera O, Gomez-Guerrero C, Ayuso C, Ortiz A, Rojo F, Egido J, Garcia-Foncillas J, Minguez P, Alvarez-Llamas G; DiabetesCancerConnect Consortium.

Mol Oncol. 2019 Sep;13(9):1887-1897. doi: 10.1002/1878-0261.12531. Epub 2019 Jul 27.

6.

Molecular evidence of field cancerization initiated by diabetes in colon cancer patients.

Del Puerto-Nevado L, Minguez P, Corton M, Solanes-Casado S, Prieto I, Mas S, Sanz AB, Gonzalez-Alonso P, Villaverde C, Portal-Nuñez S, Aguilera O, Gomez-Guerrero C, Esbrit P, Vivanco F, Gonzalez N, Ayuso C, Ortiz A, Rojo F, Egido J, Alvarez-Llamas G, Garcia-Foncillas J; DiabetesCancerConnect Consortium.

Mol Oncol. 2019 Apr;13(4):857-872. doi: 10.1002/1878-0261.12438. Epub 2019 Feb 16.

7.

Targeting inflammation in diabetic nephropathy: a tale of hope.

Moreno JA, Gomez-Guerrero C, Mas S, Sanz AB, Lorenzo O, Ruiz-Ortega M, Opazo L, Mezzano S, Egido J.

Expert Opin Investig Drugs. 2018 Nov;27(11):917-930. doi: 10.1080/13543784.2018.1538352. Epub 2018 Oct 23. Review.

PMID:
30334635
8.

Nrf2 Activation Provides Atheroprotection in Diabetic Mice Through Concerted Upregulation of Antioxidant, Anti-inflammatory, and Autophagy Mechanisms.

Lazaro I, Lopez-Sanz L, Bernal S, Oguiza A, Recio C, Melgar A, Jimenez-Castilla L, Egido J, Madrigal-Matute J, Gomez-Guerrero C.

Front Pharmacol. 2018 Jul 31;9:819. doi: 10.3389/fphar.2018.00819. eCollection 2018.

9.

SOCS1-targeted therapy ameliorates renal and vascular oxidative stress in diabetes via STAT1 and PI3K inhibition.

Lopez-Sanz L, Bernal S, Recio C, Lazaro I, Oguiza A, Melgar A, Jimenez-Castilla L, Egido J, Gomez-Guerrero C.

Lab Invest. 2018 Oct;98(10):1276-1290. doi: 10.1038/s41374-018-0043-6. Epub 2018 Mar 14.

10.

Structure-activity studies of peptidomimetics based on kinase-inhibitory region of suppressors of cytokine signaling 1.

La Manna S, Lopez-Sanz L, Leone M, Brandi P, Scognamiglio PL, Morelli G, Novellino E, Gomez-Guerrero C, Marasco D.

Biopolymers. 2017 Nov 20. doi: 10.1002/bip.23082. [Epub ahead of print]

PMID:
29154500
11.

Atrasentan for the treatment of diabetic nephropathy.

Egido J, Rojas-Rivera J, Mas S, Ruiz-Ortega M, Sanz AB, Gonzalez Parra E, Gomez-Guerrero C.

Expert Opin Investig Drugs. 2017 Jun;26(6):741-750. doi: 10.1080/13543784.2017.1325872. Review.

PMID:
28468519
12.

TWEAK blockade decreases atherosclerotic lesion size and progression through suppression of STAT1 signaling in diabetic mice.

Fernández-Laso V, Sastre C, Méndez-Barbero N, Egido J, Martín-Ventura JL, Gómez-Guerrero C, Blanco-Colio LM.

Sci Rep. 2017 Apr 27;7:46679. doi: 10.1038/srep46679.

13.

Colon cancer modulation by a diabetic environment: A single institutional experience.

Prieto I, Del Puerto-Nevado L, Gonzalez N, Portal-Nuñez S, Zazo S, Corton M, Minguez P, Gomez-Guerrero C, Arce JM, Sanz AB, Mas S, Aguilera O, Alvarez-Llamas G, Esbrit P, Ortiz A, Ayuso C, Egido J, Rojo F, Garcia-Foncillas J; DiabetesCancerConnect Consortium.

PLoS One. 2017 Mar 2;12(3):e0172300. doi: 10.1371/journal.pone.0172300. eCollection 2017.

14.

Interplay between HSP90 and Nrf2 pathways in diabetes-associated atherosclerosis.

Lazaro I, Oguiza A, Recio C, Lopez-Sanz L, Bernal S, Egido J, Gomez-Guerrero C.

Clin Investig Arterioscler. 2017 Mar - Apr;29(2):51-59. doi: 10.1016/j.arteri.2016.10.003. Epub 2017 Feb 7. English, Spanish.

PMID:
28188022
15.

2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications.

González N, Prieto I, Del Puerto-Nevado L, Portal-Nuñez S, Ardura JA, Corton M, Fernández-Fernández B, Aguilera O, Gomez-Guerrero C, Mas S, Moreno JA, Ruiz-Ortega M, Sanz AB, Sanchez-Niño MD, Rojo F, Vivanco F, Esbrit P, Ayuso C, Alvarez-Llamas G, Egido J, García-Foncillas J, Ortiz A; DiabetesCancerConnect Consortium.

Oncotarget. 2017 Mar 14;8(11):18456-18485. doi: 10.18632/oncotarget.14472. Review.

16.

Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.

Recio C, Lazaro I, Oguiza A, Lopez-Sanz L, Bernal S, Blanco J, Egido J, Gomez-Guerrero C.

J Am Soc Nephrol. 2017 Feb;28(2):575-585. doi: 10.1681/ASN.2016020237. Epub 2016 Sep 8.

17.

Targeting HSP90 Ameliorates Nephropathy and Atherosclerosis Through Suppression of NF-κB and STAT Signaling Pathways in Diabetic Mice.

Lazaro I, Oguiza A, Recio C, Mallavia B, Madrigal-Matute J, Blanco J, Egido J, Martin-Ventura JL, Gomez-Guerrero C.

Diabetes. 2015 Oct;64(10):3600-13. doi: 10.2337/db14-1926. Epub 2015 Jun 26.

18.

Peptide-based inhibition of IκB kinase/nuclear factor-κB pathway protects against diabetes-associated nephropathy and atherosclerosis in a mouse model of type 1 diabetes.

Oguiza A, Recio C, Lazaro I, Mallavia B, Blanco J, Egido J, Gomez-Guerrero C.

Diabetologia. 2015 Jul;58(7):1656-67. doi: 10.1007/s00125-015-3596-6. Epub 2015 Apr 28.

PMID:
25982245
19.

Gene delivery of suppressors of cytokine signaling (SOCS) inhibits inflammation and atherosclerosis development in mice.

Recio C, Oguiza A, Mallavia B, Lazaro I, Ortiz-Muñoz G, Lopez-Franco O, Egido J, Gomez-Guerrero C.

Basic Res Cardiol. 2015 Mar;110(2):8. doi: 10.1007/s00395-014-0458-1. Epub 2015 Jan 21.

PMID:
25604439
20.

Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice.

Recio C, Oguiza A, Lazaro I, Mallavia B, Egido J, Gomez-Guerrero C.

Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):1953-60. doi: 10.1161/ATVBAHA.114.304144. Epub 2014 Jul 10.

PMID:
25012131

Supplemental Content

Loading ...
Support Center